To join this case, fill out the form below
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Leap Therapeutics, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Leap Therapeutics, Inc. (“Leap” or the “Company”) (NASDAQ: LPTX), in connection with the proposed purchase of Flame Biosciences, Inc. (“Flame”).  Under the terms of the merger agreement, the Company will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame shareholders. Upon approval of the transaction, each share of the Series X non-voting convertible preferred stock will be automatically converted into 1,000 shares of common stock.

Weiss Law is investigating whether (i) Leap’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration is fair to Leap’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.